1
Claremon David A, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Ye Yuanjie, Zhao Wei: Cyclic urea and carbamate inhibitors of 11β -hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Ye Yuanjie, Zhao Wei, DAVIS Steven G, September 4, 2008: WO/2008/106128 (38 worldwide citation)

This invention relates to novel compounds of the Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further rel ...


2
Claremon David A, Zhuang Linghang, Ye Yuanjie, Singh Suresh B, Tice Colin M, Mcgeehan Gerard: Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Vitae Pharmaceuticals, Claremon David A, Zhuang Linghang, Ye Yuanjie, Singh Suresh B, Tice Colin M, Mcgeehan Gerard, DAVIS Steven G, September 24, 2009: WO/2009/117109 (38 worldwide citation)

This invention relates to novel compounds of the Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals.


3
Claremon David A, He Wei, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Zhao Wei, Zhuang Linghang, Cacatian Salvacion, Leftheris Katerina: Cyclic inhibitors of 11β-hydroxysteriod dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, He Wei, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Zhao Wei, Zhuang Linghang, Cacatian Salvacion, Leftheris Katerina, DAVIS Steven G, February 5, 2009: WO/2009/017664 (33 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modu ...


4
Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, Wery Jean Pierre: Diaminoalkane aspartic protease inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, Wery Jean Pierre, DAVIS Steven G, April 20, 2006: WO/2006/042150 (13 worldwide citation)

Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the ...


5
Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Simpson Robert D, Singh Suresh B, Zhao Wei, Flaherty Patrick T: Aspartic protease inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Simpson Robert D, Singh Suresh B, Zhao Wei, Flaherty Patrick T, ABELLEIRA Susan M, June 21, 2007: WO/2007/070201 (8 worldwide citation)

The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions compris ...


6

7
Baldwin John J, Claremon David A, Tice Colin M, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B: Renin inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin M, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, DAVIS Steven G, October 18, 2007: WO/2007/117559 (8 worldwide citation)

Described are compounds of the formula ( I ) which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein ...


8
Baldwin John J, Claremon David A, Tice Colin M, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T: Piperidine derivatives as renin inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin M, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, DAVIS Steven G, March 27, 2008: WO/2008/036216 (6 worldwide citation)

The present invention is directed to aspartic protease inhibitors represented by the following structural formula; or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I ...


9
Baldwin John J, Claremon David A, Tice Colin M, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T: Diaminopropanol renin inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin M, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, DAVIS Steven G, October 18, 2007: WO/2007/117557 (5 worldwide citation)

Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated. levels of renin activity or in the treatment of aspartic protease mediated disorders. Also described is a method ...


10
Baldwin John J, Cacatian Salvacion, Claremon David A, Dillard Lawrence W, Flaherty Patrick T, Ishchenko Lexey V, Mcgeehan Gerard, Simpson Robert D, Singh Suresh B, Tice Colin M, Xu Zhenrong, Yuan Jing, Zhao Wei: Renin inhibitors. Vitae Pharmaceuticals, Baldwin John J, Cacatian Salvacion, Claremon David A, Dillard Lawrence W, Flaherty Patrick T, Ishchenko Lexey V, Mcgeehan Gerard, Simpson Robert D, Singh Suresh B, Tice Colin M, Xu Zhenrong, Yuan Jing, Zhao Wei, DAVIS Steven G, December 24, 2008: WO/2008/156817 (5 worldwide citation)

Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic proteas ...